Michael Schön is currently a Solutions Owner for Clinical Biomarker Solutions at AstraZeneca. They previously worked as a Project Manager and Development Engineer at Bristol Myers Squibb, where they led the development and regulatory strategy for innovative medical devices. Michael co-founded BiotINK, serving as the Head of Device Development, and has experience as a working student in bioprinting and mechatronics at Hochschule München. They hold a Bachelor of Science in Engineering from Technische Universität München.
This person is not in the org chart
This person is not in any teams
This person is not in any offices